Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 pharmacokinetic study of improved-solubility pazopanib formulation PazSol001
NL-OMON43192Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of PazSol001 and pazopanib in renal cell carcinoma (RCC) and cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Plasma concentration of pazopanib. Started Nov 2016; status: recruiting.
02
Drugs
PazSol001pazopanib
03
Conditions
renal cell carcinoma (RCC)cancer
Beyond the preview
Go deeper on NL-OMON43192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43192.